Roniciclib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Roniciclib is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Roniciclib selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are often dysregulated in cancerous cells.
Einzelnachweise
[1] GERHARD SIEMEISTER. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.[J]. Molecular Cancer Therapeutics, 2012, 11 10: 2265-2273. DOI:
10.1158/1535-7163.MCT-12-0286.
[2] DR. ULRICH LüCKING. The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer[J]. ChemMedChem, 2013, 8 7: 1067-1085. DOI:
10.1002/cmdc.201300096.
Roniciclib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
